RLAY
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY) has 7 SEC Form 4 filings (16 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 8, 2026.
The most active filer is Chief Financial Officer Catinazzo Thomas with 3 filings. Insiders have net sold $7.4M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Sanjiv K. Patel
- Employees:259
- HQ:Cambridge, MA, US
- IPO:2020-07-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7.4M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$3.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Financial Officer | Sale | 17,717 | $331K | Jul 8 | SEC ↗ | |
| President, R&D | Sale | 8,660 | $162K | Jul 8 | SEC ↗ | |
Patel SanjivFirst filing | President and CEO | Sale | 48,199 | $944K | Jul 8 | SEC ↗ |
Rahmer PeterFirst filing | See remarks | Sale | 50,000 | $955K | Jul 2 | SEC ↗ |
| Chief Financial Officer | Sale | 187,163 | $3.2M | Jun 24 | SEC ↗ | |
Bergstrom Donald AFirst filing | President, R&D | Sale | 93,456 | $1.6M | Jun 24 | SEC ↗ |
Catinazzo ThomasFirst filing | Chief Financial Officer | Sale | 17,717 | $228K | May 14 | SEC ↗ |
Related companies
Relay Therapeutics, Inc. is in the Healthcare sector.